<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e0279078-016d-48fd-8de1-c894422b33ff"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">TRAVASOL</content> safely and effectively.  See full prescribing information for <content styleCode="bold">TRAVASOL</content>.<br/>
      <br/>TRAVASOL (amino acids) injection, for intravenous use<br/>Initial U.S. Approval: <content styleCode="bold">1984</content>
   </title>
   <effectiveTime value="20201007"/>
   <setId root="8543b5be-0f43-4891-9e56-d7c39fe839b5"/>
   <versionNumber value="16"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="189326168" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194684502" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="370353835" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter SA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="059140764" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f59c6640-584a-464b-bd2b-cc45d6ce246d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20171116"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-0644" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Travasol</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Leucine, Phenylalanine, Lysine hydrochloride, Methionine, Isoleucine, Valine, Histidine, Threonine, Tryptophan, Alanine, Glycine, Arginine, Proline, Tyrosine, Serine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="730"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEUCINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEUCINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="560"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="47E5O17Y3R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENYLALANINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="47E5O17Y3R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENYLALANINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="580"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JNJ23Q2COM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LYSINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="K3Z4F929H6" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LYSINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="400"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHIONINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHIONINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="600"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="04Y7590D77" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOLEUCINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="04Y7590D77" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ISOLEUCINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="580"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="HG18B9YRS7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VALINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="HG18B9YRS7" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="480"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HISTIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="420"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2ZD004190S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>THREONINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2ZD004190S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>THREONINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="180"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8DUH1N11BX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRYPTOPHAN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="8DUH1N11BX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRYPTOPHAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="2.07"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OF5P57N2ZX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALANINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="OF5P57N2ZX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ALANINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="1.03"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TE7660XO1C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TE7660XO1C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GLYCINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="1.15"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ARGININE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="680"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9DLQ4CIU6V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROLINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9DLQ4CIU6V" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PROLINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="42HK56048U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TYROSINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="42HK56048U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TYROSINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="452VLY9402" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SERINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="452VLY9402" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SERINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0644-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19840823"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0644-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19840823"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2000"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0644-06" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19840823"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA018931" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19840823"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_594B6A95-4D6D-4EF2-9DD2-2CC513F6D2F7">
               <id root="e4a108e1-1eae-4cc7-9da3-4b17d03fe257"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20201007"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <paragraph>Dosage and Administration, Preparation Instructions for </paragraph>
                        <paragraph>Admixing Using a Parenteral Nutrition Container (<linkHtml href="#ID_96087954-5A29-43F8-BE3E-0206264D201D">2.3</linkHtml>)	09/2020</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_8AB577C3-F2C3-47BF-BF4D-8EB151FDC4E2">
               <id root="c7f56d51-22a3-4351-8d49-16c4f725c102"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>TRAVASOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. TRAVASOL may be used to treat negative nitrogen balance in patients.</paragraph>
               </text>
               <effectiveTime value="20201007"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TRAVASOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. TRAVASOL may be used to treat negative nitrogen balance in patients. <linkHtml href="#ID_8AB577C3-F2C3-47BF-BF4D-8EB151FDC4E2">(1)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_C00A183D-6CB7-4C03-AC12-9C9C161B1F92">
               <id root="b457907b-41fc-4428-b42d-cc2ff0bb6ad3"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20201007"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Pharmacy Bulk Package. Not for direct intravenous infusion. <linkHtml href="#ID_1F847B0D-21C5-455B-A105-9CD73E6C0044">(2.1)</linkHtml>
                              </content>
                           </item>
                           <item>
                              <caption>•</caption>See full prescribing information for information on preparation, administration, instructions for use, dosing considerations, including the recommended dosage in adults and pediatrics, and dosage modifications in patients with renal impairment. (<linkHtml href="#ID_1F847B0D-21C5-455B-A105-9CD73E6C0044">2.1</linkHtml>, <linkHtml href="#ID_9514FA93-C2B7-44A8-A55B-80B63B3A9224">2.2</linkHtml>, <linkHtml href="#ID_96087954-5A29-43F8-BE3E-0206264D201D">2.3</linkHtml>, <linkHtml href="#ID_F94265AE-7473-427D-85F8-6C8A37DFBED0">2.4</linkHtml>, <linkHtml href="#ID_5ae85769-2708-432b-9550-c8cfae2928d0">2.5</linkHtml>, <linkHtml href="#ID_890ae4bc-147e-41db-8044-3d921aad9066">2.6</linkHtml>, <linkHtml href="#ID_cdb72a49-5810-4d04-aaf2-5acf18aa71a1">2.7</linkHtml>, <linkHtml href="#ID_23076da1-d1e7-460f-ba3c-9d6b42a41300">2.8</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Protect the admixed parenteral nutrition solution from light. (<linkHtml href="#ID_96087954-5A29-43F8-BE3E-0206264D201D">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_1F847B0D-21C5-455B-A105-9CD73E6C0044">
                     <id root="fec1d814-af30-4a44-a230-64265be06679"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Preparation Information</title>
                     <text>
                        <paragraph>TRAVASOL is supplied as a pharmacy bulk package <content styleCode="italics">for admixing only </content>and is <content styleCode="italics">not for direct intravenous infusion</content>. Prior to administration, TRAVASOL <content styleCode="italics">must be transferred to a separate parenteral nutrition container, diluted </content>and used as an admixture with or without dextrose, electrolytes and/or lipid emulsion.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>The key factor in preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients.</item>
                           <item>
                              <caption>•</caption>Do not remove container from overpouch until ready to use.</item>
                           <item>
                              <caption>•</caption>Tear protective overpouch across top at slit and remove solution container. Small amounts of moisture may be found on the solution container from water permeating from inside the container. The amount of permeated water is insufficient to affect the solution significantly. If larger amounts of water are found, the container should be checked for tears or leaks.</item>
                           <item>
                              <caption>•</caption>Inspect TRAVASOL prior to use.  Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. </item>
                           <item>
                              <caption> </caption>Evaluate the following:</item>
                           <item>
                              <caption> </caption>
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired.</item>
                                 <item>
                                    <caption>o</caption>Check to ensure the solution is clear, colorless or slightly yellow. Discard if the solution is bright yellow or yellowish brown. </item>
                                 <item>
                                    <caption>o</caption>Check for minute leaks by squeezing inner container. If leaks are found, discard container.</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>TRAVASOL is intended for use in the preparation of sterile, intravenous admixtures. Because additives may be incompatible with TRAVASOL, evaluate all additions for compatibility.</item>
                        </list>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9514FA93-C2B7-44A8-A55B-80B63B3A9224">
                     <id root="cede57a8-4ee0-49e8-84b3-c8228986e213"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Administration Instructions</title>
                     <text>
                        <paragraph>TRAVASOL is <content styleCode="italics">for admixing use only.  It is not for direct intravenous infusion.</content>  Prior to administration, TRAVASOL <content styleCode="italics">must be diluted</content> with other compatible intravenous fluids or used as an admixture with or without dextrose, electrolytes and/or lipid emulsion.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>TRAVASOL is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). The key factor in the preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients.</item>
                           <item>
                              <caption>•</caption>TRAVASOL is for admixing with dextrose injection and/or lipid emulsions using a parenteral nutrition container.  </item>
                           <item>
                              <caption>•</caption>When TRAVASOL is admixed with dextrose injection and/or lipid emulsion, the choice of a central or peripheral venous route should depend on the osmolarity of the final infusate.  Solutions with greater than 5% dextrose or with osmolarity of 900 mOsm/L or greater must be infused through a central venous catheter <content styleCode="italics">[see <linkHtml href="#ID_cdd06e8c-49b3-488c-9188-8c65bcb9c629">Warnings and Precautions (5.6)</linkHtml>].</content>
                           </item>
                           <item>
                              <caption>•</caption>Use a dedicated line for parenteral nutrition solutions.</item>
                           <item>
                              <caption>•</caption>Intravenous lipid emulsions can be infused concurrently into the same vein as TRAVASOL-dextrose solutions by a Y-connector located near the infusion site; flow rates of each solution should be controlled separately by infusion pumps.</item>
                           <item>
                              <caption>•</caption>For administration without lipid emulsion, use a 0.22 micron in-line filter. If lipid emulsion is also administered, use a 1.2 micron in-line filter </item>
                           <item>
                              <caption>•</caption>To prevent air embolism, use a non-vented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible containers in series, fully evacuate residual gas in the container prior to administration, do not pressurize the flexible container to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the container runs dry. </item>
                           <item>
                              <caption>•</caption>If admixed or infused with lipid emulsion, do not use administration sets and lines that contain di-2-ethylhexyl phthalate (DEHP). Administration sets that contain polyvinyl chloride (PVC) components have DEHP as a plasticizer.</item>
                           <item>
                              <caption>•</caption>Calcium and phosphate ratios must be considered. Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium phosphate precipitates <content styleCode="italics">[see <linkHtml href="#ID_2c581645-6241-4b5f-8cdc-1e6645f058f7">Warnings and Precautions (5.1)</linkHtml>].</content>
                           </item>
                           <item>
                              <caption>•</caption>Prior to infusion, visually inspect the diluted parenteral nutrition solution containing TRAVASOL for particulate matter. The solution should be clear and there should be no precipitates.  A slight yellow color does not alter the quality and efficacy of this product.  If lipid has been added, ensure the emulsion has not separated. Separation of the emulsion can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the mixed emulsion.  Discard the admixture if any of the above are observed.</item>
                        </list>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_96087954-5A29-43F8-BE3E-0206264D201D">
                     <id root="dd85665a-42a4-4f35-889d-d80306fcd059"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">2.3 Preparation Instructions for Admixing Using a Parenteral Nutrition Container</content>
                     </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption> Open by tearing protective overwrap across top at slit and remove solution container. If overpouch has been previously opened or is damaged, discard solution. </item>
                           <item>
                              <caption>•</caption>If the outlet port protector is damaged, detached, or not present, discard the container.</item>
                           <item>
                              <caption>•</caption>Some opacity of the plastic due to moisture absorption during the sterilization process may be observed.  </item>
                           <item>
                              <caption>•</caption>Check for minute leaks by squeezing the inner container firmly.  If leaks are found, discard solution.</item>
                           <item>
                              <caption>•</caption>Once the protective foil overwrap has been removed, suspend container from eyelet support.</item>
                           <item>
                              <caption>•</caption>Remove plastic protector from outlet port at bottom of container. </item>
                           <item>
                              <caption>•</caption>Attach solution transfer set. Refer to complete directions accompanying set. Note: The closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. </item>
                           <item>
                              <caption>•</caption>Prepare the admixture into the parenteral nutrition container using strict aseptic techniques to avoid microbial contamination.</item>
                           <item>
                              <caption>•</caption>Do not add the lipid emulsion to the parenteral nutrition container first; destabilization of the lipid emulsion may occur from such an admixture.</item>
                           <item>
                              <caption>•</caption>TRAVASOL may be mixed with dextrose injection and/or lipid emulsion.  The following proper mixing sequence must be followed to minimize pH related problems by ensuring that typically acidic dextrose injections are not mixed with lipid emulsions alone: <list listType="unordered">
                                 <item>
                                    <caption>1.</caption>Transfer dextrose injection to the parental nutrition pooling container.  </item>
                                 <item>
                                    <caption>2.</caption>Transfer amino acid injection. </item>
                                 <item>
                                    <caption>3.</caption>Transfer lipid emulsion.</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Because additives may be incompatible, evaluate all additions to the parenteral nutrition container for compatibility and stability of the resulting preparation. Consult with pharmacist, if available. Questions about compatibility may be directed to Baxter. If it is deemed advisable to introduce additives to the parenteral nutrition container, use aseptic technique.  </item>
                           <item>
                              <caption>•</caption>Use gentle agitation during admixing to minimize localized concentration effects; shake containers gently after each addition.</item>
                           <item>
                              <caption>•</caption>Alternatively, simultaneous transfer to the parenteral nutrition container of TRAVASOL, dextrose injection and lipid emulsion is also permitted.</item>
                           <item>
                              <caption>•</caption>For admixing using an automated device, refer to Instructions for Use of the applicable device.</item>
                           <item>
                              <caption>•</caption>The prime destabilizers of emulsions are excessive acidity (such as pH below 5) and inappropriate electrolyte content. Give careful consideration to additions of divalent cations (Ca++ and Mg++), which have been shown to cause emulsion instability. Amino acid solutions exert buffering effects that protect the emulsion.</item>
                           <item>
                              <caption>•</caption>Inspect the final parenteral nutrition solution containing TRAVASOL to ensure that:<list listType="unordered">
                                 <item>
                                    <caption>o</caption>Precipitates have not formed during the mixing or addition of additives.</item>
                                 <item>
                                    <caption>o</caption>The emulsion has not separated. Separation of the emulsion can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the admixed emulsion.</item>
                                 <item>
                                    <caption>o</caption>Discard the admixture if any of the above are observed.</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Containers should not be written on directly since ink migration has not been investigated. Affix accompanying label for date and time of entry.<paragraph>
                                 <content styleCode="underline">Stability and Storage</content>
                              </paragraph>
                           </item>
                           <item>
                              <caption>•</caption>Use for admixing should be limited to up to 4 hours at room temperature (25ºC/77ºF)  after the container closure has been penetrated.</item>
                           <item>
                              <caption>•</caption>Admixtures should be used promptly with storage under refrigeration 2° to 8°C (36° to 46°F) not to exceed 24 hours and must be completely used within 24 hours after removal from refrigeration.  Any mixture remaining must be discarded.</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">Protect the admixed parenteral nutrition solution from light.</content>
                           </item>
                           <item>
                              <caption>•</caption>For single use only. Discard used container of TRAVASOL.</item>
                        </list>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_F94265AE-7473-427D-85F8-6C8A37DFBED0">
                     <id root="81bf8d30-2258-4648-9e5a-f2841b35b6d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosing Considerations</title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>TRAVASOL is for <content styleCode="italics">admixing only</content>.  <content styleCode="italics">It is not for direct intravenous infusion</content>.  Prior to administration, TRAVASOL <content styleCode="italics">must be diluted</content> with other compatible intravenous fluids or used as an admixture with or without dextrose, electrolytes and lipid emulsion.</item>
                           <item>
                              <caption>•</caption>TRAVASOL is a part of the parenteral nutrition regimen which also includes dextrose, electrolytes, and lipid emulsion. Protein, caloric, fluid and electrolyte requirements all need to be taken into consideration when determining individual patient dosage needs.</item>
                           <item>
                              <caption>•</caption>The dosage of the final parenteral nutrition solution containing TRAVASOL must be based on the concentrations of all components in the solution and the recommended nutritional requirements <content styleCode="italics">[see <linkHtml href="#ID_5ae85769-2708-432b-9550-c8cfae2928d0">Dosage and Administration (2.5</linkHtml>, <linkHtml href="#ID_890ae4bc-147e-41db-8044-3d921aad9066">2.6</linkHtml>, <linkHtml href="#ID_cdb72a49-5810-4d04-aaf2-5acf18aa71a1">2.7</linkHtml>)]. </content>Consult the prescribing information of all added components to determine the recommended nutritional requirements for dextrose and lipid emulsion, as applicable.</item>
                           <item>
                              <caption>•</caption>The dosage of TRAVASOL should be individualized based on the patient’s clinical condition (ability to adequately metabolize amino acids), body weight and nutritional/fluid requirements, as well as additional energy given orally/enterally to the patient. Prior to initiating parenteral nutrition, the following patient information should be reviewed: review of all medications, gastrointestinal function and laboratory data (such as electrolytes (including magnesium, calcium, and phosphorus), glucose, urea/creatinine, liver panel, complete blood count and triglyceride level (if adding lipid emulsion)). </item>
                           <item>
                              <caption>•</caption>Lipid emulsion administration should be considered with prolonged use (more than 5 days) of parenteral nutrition and is required in order to prevent essential fatty acid deficiency (EFAD). Serum lipids should be monitored for evidence of EFAD in patients maintained on fat-free parenteral nutrition.  See complete prescribing information of lipid emulsion.</item>
                           <item>
                              <caption>•</caption>Prior to administration of parenteral nutrition solution containing TRAVASOL, correct severe fluid, electrolyte and acid-base disorders.</item>
                           <item>
                              <caption>•</caption>In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria.</item>
                           <item>
                              <caption>•</caption>Monitor levels of serum potassium during parenteral nutrition therapy. It may be necessary to add additional potassium to the parenteral nutrition admixture.</item>
                        </list>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5ae85769-2708-432b-9550-c8cfae2928d0">
                     <id root="6bd53bf7-7db3-41bf-bec2-cb3948ca7f81"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>	2.5 Recommended Dosage in Adults 	</title>
                     <text>
                        <paragraph>The recommended adult daily dosage of TRAVASOL and the nutritional requirements for protein (nitrogen) are shown in <linkHtml href="#_Ref416168966">Table 1</linkHtml>. </paragraph>
                        <paragraph>As a component of parenteral nutrition, TRAVASOL provides 0.1 g protein/mL, which corresponds to 0.0165 g nitrogen/mL.</paragraph>
                        <paragraph>As indicated on an individual basis, vitamins, electrolytes, trace elements and other components (including dextrose, electrolytes and lipid emulsion) can be added to the parenteral nutrition solution to meet nutrient needs and prevent deficiencies and complications from developing. </paragraph>
                        <paragraph>A maximum fluid supply of 40 mL/kg/day of parenteral nutrition solution, based on protein, should not be exceeded in adult patients; this volume does not take carbohydrates or electrolytes into consideration.</paragraph>
                        <paragraph>The flow rate of the parenteral nutrition solution must be adjusted taking into account the dose being administered, the daily volume intake, and the duration of the infusion. The flow rate should be increased gradually and governed, especially during the first few days of therapy, by the patient’s tolerance to dextrose. Daily intake of TRAVASOL and dextrose should be increased gradually to the maximum required dose as indicated by frequent determinations of blood glucose levels.</paragraph>
                        <table ID="_Ref416168966" styleCode="Noautorules" width="100%">
                           <caption>Table 1. Recommended Daily Dosage in Adults</caption>
                           <col width="20%"/>
                           <col width="31%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Adult Patient Population</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Recommended <br/>Protein</content>
                                       <footnote ID="_Ref416246116">Protein is provided as amino acids. When infused intravenously, amino acids are metabolized and utilized as the building blocks of protein.</footnote>
                                       <content styleCode="bold"> Requirement <br/>(g/kg/day)</content>
                                       <linkHtml href="#ID_1178A9B4-B14D-40CF-9044-9CD398E6676F">1</linkHtml>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Corresponding Nitrogen Requirement <br/>(g/kg/day)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Recommended Daily Dosage of TRAVASOL <br/>(mL/kg/day)</content>
                                       <footnote ID="_Ref416246169">A maximum fluid supply of 40 mL/kg/day of parenteral nutrition solution should not be exceeded in adult patients.</footnote>
                                       <content styleCode="bold"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Stable Patients</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.8 to 1.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.13 to 0.16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>8 to 10</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Critically Ill Patients<footnote ID="_Ref499721204">Includes patients requiring more than 2 to 3 days in the intensive care unit with organ failure, sepsis or postoperative major surgery.  Do not use in patients with conditions that are contraindicated <content styleCode="italics">[see <linkHtml href="#ID_90F45FD0-C409-45DE-8D93-060560BFF8FA">Contraindications (4)</linkHtml>]</content>.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1.5 to 2.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0.24 to 0.32</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>15 to 20</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_890ae4bc-147e-41db-8044-3d921aad9066">
                     <id root="3e67923b-31b5-4e4d-baef-63af8147e43c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Modifications in Patients with Renal Impairment </title>
                     <text>
                        <paragraph>Prior to administration, correct severe fluid or electrolyte imbalances. Closely monitor serum electrolyte levels and adjust the volume of parenteral nutrition administered as required <content styleCode="italics">[see <linkHtml href="#ID_5c8d643b-c601-4f26-9a48-01aec9bc8490">Warnings and Precautions (5.10)</linkHtml>]</content>.</paragraph>
                        <paragraph>Patients with renal impairment not needing dialysis require 0.6 to 0.8 g of protein/kg/day.  Serum electrolyte levels should be closely monitored.  Patients on hemodialysis or continuous renal replacement therapy should receive 1.2 to 1.8 g of protein/kg/day up to a maximum of 2.5 g of protein/kg/day based on nutritional status and estimated protein losses.<sup>2</sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20171116"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_cdb72a49-5810-4d04-aaf2-5acf18aa71a1">
                     <id root="853f1579-2c4f-4b9b-a038-30376226234f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Recommended Dosage in Pediatric Patients </title>
                     <text>
                        <paragraph>The dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia <content styleCode="italics">[see <linkHtml href="#ID_2A7C6EEE-E68D-4804-A02C-450CF76BFC89">Use in Specific Populations (8.4)</linkHtml>]</content>. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.  The infusion rate and volume should be determined by the consulting physician experienced in pediatric intravenous fluid therapy. </paragraph>
                        <paragraph>In pediatric patients, TRAVASOL is dosed on the basis of protein provided as amino acids.  The recommended dosage, by age group is provided in <linkHtml href="#_Ref499718044">Table 2</linkHtml>.</paragraph>
                        <paragraph>Infusion rates are based on protein and do not take carbohydrates, fluid or electrolytes into consideration.</paragraph>
                        <paragraph>TRAVASOL does not contain the amino acids cysteine and taurine, considered conditionally essential for neonates and infants. If possible, these amino acids should be added to the parenteral nutrition admixture if used in this pediatric population.</paragraph>
                        <table width="100%">
                           <col width="26%"/>
                           <col width="24%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <thead>
                              <tr>
                                 <th align="left" colspan="4" valign="top">Table 2. Recommended Daily Dosage in Pediatric Patients</th>
                              </tr>
                              <tr>
                                 <th align="left" styleCode="Rrule Lrule Botrule " valign="bottom">Age</th>
                                 <th align="left" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">Recommended Protein<sup>a</sup> Requirement (g/kg/day)<sup>1</sup>
                                 </th>
                                 <th align="left" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">Corresponding Nitrogen Requirement (g/kg/day)</th>
                                 <th align="left" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">Recommended Daily Dosage of TRAVASOL (mL/kg/day)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Preterm and term infants less than 1 month of age</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3 to 4</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.48 to 0.64</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>30 to 40</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pediatric patients  1 month to less than 1 year of age</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>2 to 3</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.32 to 0.48</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>20 to 30</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pediatric patients 1 to 10 years of age</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1 to 2</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.16 to 0.32</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>10 to 20</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Pediatric patients greater than 10 to less than 17 years of age</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.8 to 1.5</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.13 to 0.24</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>8 to 15</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" styleCode="Toprule " valign="top">
                                    <list listType="ordered">
                                       <item>
                                          <caption>a</caption>Protein is provided as amino acids. When infused intravenously, amino acids are metabolized and utilized as the building blocks of protein.</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_23076da1-d1e7-460f-ba3c-9d6b42a41300">
                     <id root="30583aac-b74f-4faf-a8da-39663f731092"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.8 Discontinuation of Parenteral Nutrition </title>
                     <text>
                        <paragraph>To reduce the risk of hypoglycemia after discontinuation, a gradual decrease in flow rate in the last hour of infusion should be considered when administering parenteral nutrition solutions containing dextrose.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3A044FF1-2A25-4AA5-A6B5-6F328988AB68">
               <id root="c1a31949-3145-4055-9050-49a478a1b3e3"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>TRAVASOL 10% is a sterile solution of 10 grams of amino acids per 100 mL (0.1 gram/mL) available in 500 mL, 1000 mL, and 2000 mL flexible containers, which contain essential and nonessential amino acids. <linkHtml href="#_Ref499733154">Table 3</linkHtml> describes the individual components of TRAVASOL.</paragraph>
                  <table width="100%">
                     <col width="41%"/>
                     <col width="17%"/>
                     <thead>
                        <tr>
                           <th align="left" colspan="2" valign="top">Table 3. Ingredients per 100 mL of TRAVASOL</th>
                        </tr>
                        <tr>
                           <th align="left" styleCode="Rrule Lrule Botrule " valign="bottom">Amino Acids</th>
                           <th align="left" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">10 g</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Total Nitrogen</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>1.65 g</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Essential Amino Acids</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Leucine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>730 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Isoleucine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>600 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Lysine (added as the hydrochloride salt)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>580 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Valine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>580 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Phenylalanine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>560 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Histidine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>480 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Threonine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>420 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Methionine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>400 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Tryptophan</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>180 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Nonessential Amino Acids</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Alanine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>2.07 g</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Arginine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>1.15 g</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Glycine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>1.03 g</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Proline</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>680 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Serine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>500 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Tyrosine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>40 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Anion profiles per liter</content>
                                 <footnote ID="_Ref499721860">Balanced by ions from amino acids.</footnote>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Acetate<footnote ID="_Ref499721975">Derived from pH adjustment with glacial acetic acid. </footnote>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>88 mEq</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Chloride<footnote ID="_Ref499721982">Contributed by the Lysine Hydrochloride.</footnote>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>40 mEq</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>pH (Range); pH adjusted with glacial acetic acid</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>6.0 (5.0 to 7.0)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Osmolarity (calc)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>998 mOsm/L</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Toprule " valign="top"/>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20201007"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 10% (0.1 grams/mL), 10 grams of amino acid solution per 100 mL in 500 mL, 1000 mL, and 2000 mL flexible containers. <linkHtml href="#ID_3A044FF1-2A25-4AA5-A6B5-6F328988AB68">(3)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_90F45FD0-C409-45DE-8D93-060560BFF8FA">
               <id root="6f79d724-4e47-48f6-bb9c-0aa7f4e4faa2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>The use of TRAVASOL is contraindicated in:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Patients with known hypersensitivity to one or more amino acids <content styleCode="italics">[see <linkHtml href="#ID_06cf0928-5448-4727-a00b-9f1f031a61a3">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                     <item>
                        <caption>•</caption>Patients with inborn errors of amino acid metabolism due to risk of severe metabolic or neurologic complications.</item>
                     <item>
                        <caption>•</caption>Patients with pulmonary edema or acidosis due to low cardiac output.</item>
                  </list>
               </text>
               <effectiveTime value="20201007"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Known hypersensitivity to one or more amino acids. <linkHtml href="#ID_90F45FD0-C409-45DE-8D93-060560BFF8FA">(4)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>Inborn errors of amino acid metabolism. <linkHtml href="#ID_90F45FD0-C409-45DE-8D93-060560BFF8FA">(4)</linkHtml>
                              <paragraph>Patients with pulmonary edema or acidosis due to low cardiac output. <linkHtml href="#ID_90F45FD0-C409-45DE-8D93-060560BFF8FA">(4)</linkHtml>
                              </paragraph>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_7A412752-6D7D-40AC-823E-ED21A5D39A19">
               <id root="8cbca40c-a116-471d-a90e-f93fc156b2a3"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20201007"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Pulmonary Embolism due to Pulmonary Vascular Precipitates:</content> if signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. <linkHtml href="#ID_2c581645-6241-4b5f-8cdc-1e6645f058f7">(5.1)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hypersensitivity Reactions</content>: monitor for signs and symptoms and discontinue infusion if reactions occur. <linkHtml href="#ID_06cf0928-5448-4727-a00b-9f1f031a61a3">(5.2)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Risk of Infections, Refeeding Complications, and Hyperglycemia or Hyperosmolar Hyperglycemic State</content>: monitor for signs and symptoms; monitor laboratory parameters. <linkHtml href="#ID_418ae3cd-c319-42ae-889f-6ae77ed072bb">(5.3</linkHtml>, <linkHtml href="#ID_93b1819b-88e2-4106-877e-70f0363e72bb">5.4</linkHtml>, <linkHtml href="#ID_7cc66c01-4492-4e1a-b662-e01fad00175d">5.5)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Vein Damage and Thrombosis:</content>  solutions with osmolarity of 900 mOsm/L or more must be infused through a central catheter. <linkHtml href="#ID_9514FA93-C2B7-44A8-A55B-80B63B3A9224">(2.2</linkHtml>, <linkHtml href="#ID_cdd06e8c-49b3-488c-9188-8c65bcb9c629">5.6)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hepatobiliary Disorders:</content>  monitor liver function parameters and ammonia levels. <linkHtml href="#ID_3ee45b92-3db4-4fd4-b16b-a5bc63cee797">(5.7)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Aluminum Toxicity:</content>  increased risk in patients with renal impairment, including preterm infants. <linkHtml href="#ID_6ebe023c-1a4a-4275-a7f4-66ddf5f777b1">(5.8</linkHtml>, <linkHtml href="#ID_2A7C6EEE-E68D-4804-A02C-450CF76BFC89">8.4)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Parenteral Nutrition Associated Liver Disease:</content>  increased risk in patients who receive parenteral nutrition for extended periods of time, especially preterm infants; monitor liver function tests, if abnormalities occur consider discontinuation or dosage reduction. <linkHtml href="#ID_8a6fbf0c-fbaa-4b76-b8cd-7eb740171a7f">(5.9</linkHtml>, <linkHtml href="#ID_2A7C6EEE-E68D-4804-A02C-450CF76BFC89">8.4)</linkHtml>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Electrolyte Imbalance and Fluid Overload:</content>  patients with cardiac insufficiency or renal impairment may require adjustment of fluid, protein and electrolyte content. <linkHtml href="#ID_5c8d643b-c601-4f26-9a48-01aec9bc8490">(5.10</linkHtml>, <linkHtml href="#ID_2A7C6EEE-E68D-4804-A02C-450CF76BFC89">8.4)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_2c581645-6241-4b5f-8cdc-1e6645f058f7">
                     <id root="57c6e492-e560-4806-b064-1e3c6a884cba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Pulmonary Embolism due to Pulmonary Vascular Precipitates </title>
                     <text>
                        <paragraph>Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition, including TRAVASOL.  In some cases, fatal outcomes due to pulmonary embolism have occurred.  TRAVASOL contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates.  Precipitates have been reported even in the absence of phosphate salt in the solution.  Precipitation following passage through an in-line filter and suspected in vivo precipitate formation has also been reported.  If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation.  In addition to inspection of the solution <content styleCode="italics">[see <linkHtml href="#ID_1F847B0D-21C5-455B-A105-9CD73E6C0044">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#ID_9514FA93-C2B7-44A8-A55B-80B63B3A9224">2.2</linkHtml>, <linkHtml href="#ID_96087954-5A29-43F8-BE3E-0206264D201D">2.3</linkHtml>, <linkHtml href="#ID_F94265AE-7473-427D-85F8-6C8A37DFBED0">2.4</linkHtml>)]</content>, the infusion set and catheter should also periodically be checked for precipitates.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_06cf0928-5448-4727-a00b-9f1f031a61a3">
                     <id root="82b89137-7995-4fe3-8d0f-95cc05dca47d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>Hypersensitivity reactions including anaphylaxis have been reported with parenteral nutrition solutions containing TRAVASOL.  Stop the infusion immediately and treat patient accordingly if any signs or symptoms of a hypersensitivity reaction develop. Signs or symptoms may include: hypotension, hypertension, peripheral cyanosis, tachycardia, dyspnea, vomiting, nausea, urticaria, rash, pruritus, erythema, hyperhidrosis, pyrexia, and chills.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_418ae3cd-c319-42ae-889f-6ae77ed072bb">
                     <id root="5755fd45-686a-47c7-837c-644eca4cc219"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Risk of Infections </title>
                     <text>
                        <paragraph>Patients who require parenteral nutrition are at high risk of infections because the nutritional components of these solutions can support microbial growth. Infection and sepsis may also occur as a result of the use of intravenous catheters to administer parenteral nutrition.</paragraph>
                        <paragraph>The risk of infection is increased in patients with malnutrition-associated immunosuppression, hyperglycemia exacerbated by dextrose infusion, long-term use and poor maintenance of intravenous catheters, or immunosuppressive effects of other concomitant conditions, drugs, or other components of the parenteral formulation (e.g., lipid emulsion). </paragraph>
                        <paragraph>To decrease the risk of infection, ensure aseptic technique in catheter placement and maintenance, as well as aseptic technique in the preparation and administration of the nutritional formula.</paragraph>
                        <paragraph>Monitor for signs and symptoms (including fever and chills) of early infections, including laboratory test results (including leukocytosis and hyperglycemia) and frequent checks of the parenteral access device and insertion site for edema, redness and discharge.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_93b1819b-88e2-4106-877e-70f0363e72bb">
                     <id root="82ec1439-e829-4009-a417-26cd87728ba6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Refeeding Syndrome </title>
                     <text>
                        <paragraph>Refeeding severely undernourished patients may result in refeeding syndrome, characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, monitor severely undernourished patients and slowly increase nutrient intakes.</paragraph>
                     </text>
                     <effectiveTime value="20171116"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7cc66c01-4492-4e1a-b662-e01fad00175d">
                     <id root="c6a2b7c1-a86a-4efe-920e-1b8382ea177c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hyperglycemia or Hyperosmolar Hyperglycemic State </title>
                     <text>
                        <paragraph>Administration of parenteral nutrition solutions containing dextrose in patients with diabetes mellitus, impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient’s utilization rate may lead to hyperglycemia, coma, and death. Patients with underlying confusion and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state.  Monitor blood glucose levels and treat hyperglycemia to maintain optimum levels while administering parenteral nutrition solutions containing dextrose. Insulin may be administered or adjusted to maintain optimal blood glucose levels during administration of parenteral nutrition solutions containing dextrose.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_cdd06e8c-49b3-488c-9188-8c65bcb9c629">
                     <id root="6650b090-d366-4efa-bee4-1d012f05afef"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Vein Damage and Thrombosis </title>
                     <text>
                        <paragraph>TRAVASOL must be diluted and used as an admixture with or without dextrose, electrolytes and/or lipid emulsion.  It is not for direct intravenous infusion. Solutions containing more than 5% dextrose or with an osmolarity of 900 mOsm/L or greater must be infused through a central catheter <content styleCode="italics">[see <linkHtml href="#ID_9514FA93-C2B7-44A8-A55B-80B63B3A9224">Dosage and Administration (2.2)</linkHtml>]</content>. The infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3ee45b92-3db4-4fd4-b16b-a5bc63cee797">
                     <id root="5e1a50cf-9369-4d41-9669-a23f0c90de05"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Hepatobiliary Disorders </title>
                     <text>
                        <paragraph>Hepatobiliary disorders are known to develop in some patients without preexisting liver disease who receive parenteral nutrition, including cholecystitis, cholelithiasis, cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure. The etiology of these disorders is thought to be multifactorial and may differ between patients. </paragraph>
                        <paragraph>Increase in blood ammonia levels and hyperammonemia may occur in patients receiving amino acid solutions, including TRAVASOL. In some patients this may indicate hepatic insufficiency or the presence of an inborn error of amino acid metabolism <content styleCode="italics">[see <linkHtml href="#ID_90F45FD0-C409-45DE-8D93-060560BFF8FA">Contraindications (4)</linkHtml> and <linkHtml href="#ID_2A7C6EEE-E68D-4804-A02C-450CF76BFC89">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                        <paragraph>Monitor liver function parameters and ammonia levels. Patients developing signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6ebe023c-1a4a-4275-a7f4-66ddf5f777b1">
                     <id root="c9a9a730-f2d5-4a3e-83cc-2634ab3d7b7a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Aluminum Toxicity </title>
                     <text>
                        <paragraph>TRAVASOL contains no more than 25 mcg/L of aluminum. However, with prolonged parenteral administration in patients with renal impairment, the aluminum contained in TRAVASOL may reach toxic levels.  Preterm infants are at a greater risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.</paragraph>
                        <paragraph>Patients with renal impairment, including preterm infants, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day, accumulate aluminum at levels associated with central nervous system and bone toxicity.  Tissue loading may occur at even lower rates of administration.</paragraph>
                     </text>
                     <effectiveTime value="20171116"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8a6fbf0c-fbaa-4b76-b8cd-7eb740171a7f">
                     <id root="ff5cd747-73d1-4ea8-b007-a567e48a0ea1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Risk of Parenteral Nutrition Associated Liver Disease </title>
                     <text>
                        <paragraph>Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis. The exact etiology is unknown and is likely multifactorial. If patients treated with parenteral nutrition solutions containing TRAVASOL develop liver test abnormalities, consider discontinuation or dosage reduction.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5c8d643b-c601-4f26-9a48-01aec9bc8490">
                     <id root="ff5d6629-8afb-4019-829e-08939e4ade9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Electrolyte Imbalance and Fluid Overload </title>
                     <text>
                        <paragraph>Patients with renal impairment, such as pre-renal azotemia, renal obstruction, and protein-losing nephropathy may be at increased risk of electrolyte and fluid volume imbalance. Patients with cardiac insufficiency and pulmonary congestion are susceptible to excess fluid accumulation. Use parenteral nutrition solutions containing TRAVASOL with caution in patients with cardiac insufficiency or renal impairment. The dosage of parenteral nutrition may require adjustment with specific attention to fluid, protein, and electrolyte content in these patients.</paragraph>
                        <paragraph>Monitor renal function parameters. Patients developing signs of renal impairment should be assessed early by a clinician knowledgeable in renal disease in order to determine the appropriate parenteral nutrition dosage and other treatment options.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2da099cd-e423-4820-8659-e0d7fcc7d34c">
                     <id root="aae21b95-f667-4387-9f23-ea76420074cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Monitoring/Laboratory Tests </title>
                     <text>
                        <paragraph>Monitor fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters throughout treatment.  If electrolyte levels are severely elevated, stop parenteral nutrition containing TRAVASOL until levels have been corrected.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_E758FCA9-2A06-493B-976A-15D6161CD6FC">
               <id root="b6ab41d4-b7e1-4900-8f97-649d07ced231"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Pulmonary embolism due to pulmonary vascular precipitates <content styleCode="italics">[see <linkHtml href="#ID_2c581645-6241-4b5f-8cdc-1e6645f058f7">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hypersensitivity reactions <content styleCode="italics">[see <linkHtml href="#ID_06cf0928-5448-4727-a00b-9f1f031a61a3">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Risk of Infections  <content styleCode="italics">[see <linkHtml href="#ID_418ae3cd-c319-42ae-889f-6ae77ed072bb">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Refeeding syndrome <content styleCode="italics">[see <linkHtml href="#ID_93b1819b-88e2-4106-877e-70f0363e72bb">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hyperglycemia or hyperosmolar hyperglycemic state <content styleCode="italics">[see <linkHtml href="#ID_7cc66c01-4492-4e1a-b662-e01fad00175d">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Vein damage and thrombosis <content styleCode="italics">[see <linkHtml href="#ID_cdd06e8c-49b3-488c-9188-8c65bcb9c629">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hepatobiliary disorders <content styleCode="italics">[see <linkHtml href="#ID_3ee45b92-3db4-4fd4-b16b-a5bc63cee797">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Aluminum toxicity <content styleCode="italics">[see <linkHtml href="#ID_6ebe023c-1a4a-4275-a7f4-66ddf5f777b1">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Parenteral Nutrition Associated Liver Disease <content styleCode="italics">[see <linkHtml href="#ID_8a6fbf0c-fbaa-4b76-b8cd-7eb740171a7f">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Electrolyte imbalance and fluid overload <content styleCode="italics">[see <linkHtml href="#ID_5c8d643b-c601-4f26-9a48-01aec9bc8490">Warnings and Precautions (5.10)</linkHtml>]</content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions from voluntary reports or clinical studies have been reported with TRAVASOL. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Metabolic acidosis</item>
                     <item>
                        <caption>•</caption>Alkalosis</item>
                     <item>
                        <caption>•</caption>Osmotic diuresis and dehydration, </item>
                     <item>
                        <caption>•</caption>Rebound hypoglycemia</item>
                     <item>
                        <caption>•</caption>Hypo- and hyper-vitaminosis</item>
                  </list>
               </text>
               <effectiveTime value="20201007"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions include pulmonary vascular emboli, hypersensitivity reactions infection, refeeding syndrome, hyperglycemia and hyperosmolar hyperglycemic state, vein thrombosis, elevated liver function tests, hyperammonemia, electrolyte imbalances, and  hypervolemia. <linkHtml href="#ID_E758FCA9-2A06-493B-976A-15D6161CD6FC">(6)</linkHtml>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Baxter Healthcare Corporation at 1-866-888-2472</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_48399C72-3212-4F18-BC3A-B106B25759FC">
               <id root="93c5116f-a659-4b05-9d8b-7dec52e37966"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20201007"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pediatric Use</content>: increased risk of hypoglycemia/hyperglycemia: monitor serum glucose concentrations. <linkHtml href="#ID_2A7C6EEE-E68D-4804-A02C-450CF76BFC89">(8.4)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_64FE81A7-071E-4CA1-B359-00EB8E0B5813">
                     <id root="63de3ccb-4c67-43f4-b7f5-30a9baee11b9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Limited published data with injectable amino acids solutions, including TRAVASOL in pregnant women are not sufficient to inform a drug associated risk for adverse developmental outcomes.  However, malnutrition in pregnant women is associated with adverse maternal and fetal outcomes <content styleCode="italics">[see <linkHtml href="#ID_64FE81A7-071E-4CA1-B359-00EB8E0B5813">Clinical Considerations</linkHtml>].</content>   Animal reproduction studies have not been conducted with injectable amino acids solutions, including TRAVASOL.  </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo-Fetal Risk</content>
                        </paragraph>
                        <paragraph>Severe malnutrition in pregnant women is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality. Parenteral nutrition should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_86635b1e-8bf7-42eb-9485-123ea8e74cc1">
                     <id root="434d4528-74a8-4ed7-a6b5-809a8ee86d6e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data available to assess the presence of injectable amino acids, including TRAVASOL in human milk, the effects of TRAVASOL on the breastfed infant or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of TRAVASOL to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TRAVASOL and any potential adverse effects on the breastfed child from TRAVASOL or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2A7C6EEE-E68D-4804-A02C-450CF76BFC89">
                     <id root="67a3bf42-76ea-4a91-8b82-b4c68dabab82"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects <content styleCode="italics">[see <linkHtml href="#ID_cdb72a49-5810-4d04-aaf2-5acf18aa71a1">Dosage and Administration (2.7)</linkHtml>]</content>. </paragraph>
                        <paragraph>Plasma electrolyte concentrations should be closely monitored in the pediatric patients who may have impaired ability to regulate fluids and electrolytes.</paragraph>
                        <paragraph>Hyperammonemia is of special significance in infants (birth to two years).  This reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin.  It is essential that blood ammonia be measured frequently in infants <content styleCode="italics">[see <linkHtml href="#ID_3ee45b92-3db4-4fd4-b16b-a5bc63cee797">Warnings and Precautions (5.7)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with TRAVASOL may be at risk of aluminum toxicity <content styleCode="italics">[see <linkHtml href="#ID_6ebe023c-1a4a-4275-a7f4-66ddf5f777b1">Warnings and Precautions (5.8)</linkHtml>]</content>.</paragraph>
                        <paragraph>Patients, including pediatric patients, may be at risk for PNALD <content styleCode="italics">[see <linkHtml href="#ID_8a6fbf0c-fbaa-4b76-b8cd-7eb740171a7f">Warnings and Precautions (5.9)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_BFE18DAE-66E8-4605-8BA1-CF43322FDB61">
                     <id root="fa5da98f-0f38-454a-ab4e-09afea2a9fff"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Clinical studies with TRAVASOL have not been performed to determine whether subjects aged 65 and over respond differently from other younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  </paragraph>
                        <paragraph>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e7f4636a-0208-4b29-b25b-6aecc3882363">
                     <id root="621663b3-ff6e-4e7c-81fc-b00fac0d9460"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment </title>
                     <text>
                        <paragraph>In patients with impaired renal function, parenteral nutrition solutions containing TRAVASOL should be administered with caution. Frequent clinical evaluation and laboratory tests to monitor renal function such as serum electrolytes (especially phosphate and potassium) and fluid balance should <content styleCode="italics">
                              <linkHtml href="#ID_5c8d643b-c601-4f26-9a48-01aec9bc8490">be conducted [see Dosage and Administration (2.6), Warnings and Precautions (5.10)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4ba30d0e-0f21-408a-b1b0-fd06190f48b7">
                     <id root="3bdfaa28-96ae-4899-ad31-73f0fd78744b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Hepatic Impairment </title>
                     <text>
                        <paragraph>In patients with impaired liver function, parenteral nutrition solutions containing TRAVASOL should be administered starting at the low end of the dosing range <content styleCode="italics">[see <linkHtml href="#ID_5ae85769-2708-432b-9550-c8cfae2928d0">Dosage and Administration (2.5)</linkHtml>]</content>. Frequent clinical evaluation and laboratory tests to monitor liver function such as bilirubin and liver function parameters should be conducted <content styleCode="italics">[see <linkHtml href="#ID_3ee45b92-3db4-4fd4-b16b-a5bc63cee797">Warnings and Precautions (5.7)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_E3160A77-E624-41CC-943D-36826EDFD7E2">
               <id root="f56e756b-c0eb-4fdb-bc09-5e05376399d1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>An increased infusion rate of parenteral nutrition can cause hypervolemia, electrolyte disturbances, acidosis and/or azotemia, hyperglycemia, hyperosmolality <content styleCode="italics">[see <linkHtml href="#ID_7cc66c01-4492-4e1a-b662-e01fad00175d">Warnings and Precautions (5.5</linkHtml>, <linkHtml href="#ID_5c8d643b-c601-4f26-9a48-01aec9bc8490">5.10)</linkHtml>]</content>. </paragraph>
                  <paragraph>Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal.</paragraph>
                  <paragraph>Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to respiratory and cardiovascular systems.</paragraph>
                  <paragraph>For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or <linkHtml href="file:///C:\Users\USCO-BaxEdgeProd\AppData\Local\Temp\www.poison.org">www.poison.org</linkHtml>.</paragraph>
               </text>
               <effectiveTime value="20201007"/>
            </section>
         </component>
         <component>
            <section ID="ID_FB639BE6-93EB-4ECC-9042-81EE99C1DB95">
               <id root="b858d310-1055-4e18-9a19-972b40f21a1c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>TRAVASOL 10% (amino acids) injection is a sterile, nonpyrogenic hypertonic solution of essential and nonessential amino acids supplied in a flexible container as a Pharmacy Bulk Package. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program <content styleCode="italics">[see <linkHtml href="#ID_1F847B0D-21C5-455B-A105-9CD73E6C0044">Dosage and Administration (2.1)</linkHtml>]</content>. TRAVASOL is not for direct intravenous infusion. </paragraph>
                  <paragraph>The formulas for the individual amino acids found in TRAVASOL are provided in <linkHtml href="#_Ref499717697">Table 4</linkHtml>.</paragraph>
                  <table width="100%">
                     <col width="42%"/>
                     <col width="41%"/>
                     <thead>
                        <tr>
                           <th align="left" colspan="2" valign="top">Table 4. Formulas for Amino Acids</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Essential Amino Acids</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Leucine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>(CH<sub>3</sub>)<sub>2</sub> CHCH<sub>2</sub>CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Isoleucine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>CH<sub>3</sub>CH<sub>2</sub>CH (CH<sub>3</sub>) CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Lysine (added as the hydrochloride salt)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>H<sub>2</sub>N (CH<sub>2</sub>)<sub>4</sub> CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Valine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>(CH<sub>3</sub>)<sub>2</sub> CHCH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Phenylalanine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>(C<sub>6</sub>H<sub>5</sub>) CH<sub>2</sub> CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Histidine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>(C<sub>3</sub>H<sub>3</sub>N<sub>2</sub>) CH<sub>2</sub>CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Threonine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>CH<sub>3</sub>CH (OH) CH (NH<sub>2</sub>) COO</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Methionine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>CH<sub>3</sub>S (CH<sub>2</sub>)2 CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Tryptophan</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>(C<sub>8</sub>H<sub>6</sub>N) CH<sub>2</sub> CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Nonessential Amino Acids</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Alanine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>CH<sub>3</sub>CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Arginine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>H<sub>2</sub>NC (NH) NH (CH<sub>2</sub>)3 CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Glycine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>H<sub>2</sub>NCH<sub>2</sub>COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Proline</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>[(CH<sub>2</sub>)<sub>3</sub> NH CH] COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Serine</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>HOCH<sub>2</sub>CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Tyrosine</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>[C<sub>6</sub>H<sub>4</sub> (OH)] CH<sub>2</sub>CH (NH<sub>2</sub>) COOH</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>TRAVASOL contains no more than 25 mcg/L of aluminum.</paragraph>
               </text>
               <effectiveTime value="20201007"/>
            </section>
         </component>
         <component>
            <section ID="ID_7A9CE42D-CFAC-4DF0-9260-BFECA3530C25">
               <id root="29d500c3-f036-43b8-8494-f46b2b78ec6e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20201007"/>
               <component>
                  <section ID="ID_47926033-C4F6-4C12-9D1D-AB7163BF2FA7">
                     <id root="67fddd7f-b7c8-4a52-af09-12e3bfb6d2bf"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>TRAVASOL is used as a supplement of nutrition in patients, providing amino acids parenterally.</paragraph>
                        <paragraph>The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source of energy.</paragraph>
                     </text>
                     <effectiveTime value="20201007"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1178A9B4-B14D-40CF-9044-9CD398E6676F">
               <id root="2d84e777-86b2-402b-9572-5263a427622d"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES </title>
               <text>
                  <list listType="ordered">
                     <item>
                        <caption>1.</caption>Ayers P. et al. A.S.P.E.N. Parenteral Nutrition Handbook, 2nd ed. 2014 pg. 123</item>
                     <item>
                        <caption>2.</caption>Mueller CM ed. The A.S.P.E.N. Nutrition Support Core Curriculum 2nd ed. 2012. Chapter 29 Wolk R, Foulks C. Renal Disease., pg. 500</item>
                  </list>
               </text>
               <effectiveTime value="20201007"/>
            </section>
         </component>
         <component>
            <section ID="ID_E7B937E1-5A4F-48DB-8B46-1A6F5F689824">
               <id root="1edc230c-aa1c-4797-b1ec-70e161f6ec0f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>TRAVASOL 10% (amino acids) injection is available in plastic Pharmacy Bulk Package flexible containers in the following sizes as shown in <linkHtml href="#_Ref499717820" title="Table 5">Table 5</linkHtml> below.</paragraph>
                  <table ID="_Ref499717820" styleCode="Noautorules" width="100%">
                     <caption>Table 5. TRAVASOL Dosage Forms</caption>
                     <col width="31%"/>
                     <col width="31%"/>
                     <col width="31%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Code</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>
                                    <content styleCode="bold">Volume</content>
                                 </item>
                              </list>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC Number</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>1B6623 </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <list listType="ordered">
                                 <item>
                                    <caption> </caption>500 mL</item>
                              </list>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>NDC 0338-0644-03</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>1B6624 </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>1000 mL</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>NDC 0338-0644-04</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>1B6626P </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>2000 mL</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>NDC 0338-0644-06</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Minimize exposure of TRAVASOL to heat and avoid excessive heat.</paragraph>
                  <paragraph>Protect from freezing.</paragraph>
                  <paragraph>Store TRAVASOL at room temperature (25ºC/77ºF).</paragraph>
                  <paragraph>Do not use if protective overpouch has been previously opened or damaged.</paragraph>
                  <paragraph>For storage of admixed solutions <content styleCode="italics">[see <linkHtml href="#ID_96087954-5A29-43F8-BE3E-0206264D201D">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20201007"/>
            </section>
         </component>
         <component>
            <section ID="ID_E0920B08-01A8-43E9-A95B-70EF5C735264">
               <id root="8d03021f-c180-4495-869c-4e43c3cca7ca"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Inform patients, caregivers, or home healthcare providers of the following risks of TRAVASOL:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Pulmonary embolism due to pulmonary vascular precipitates <content styleCode="italics">[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_2c581645-6241-4b5f-8cdc-1e6645f058f7">Warnings and Precautions (5.1)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hypersensitivity reactions <content styleCode="italics">[see <linkHtml href="#ID_06cf0928-5448-4727-a00b-9f1f031a61a3">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Risk of Infections <content styleCode="italics">[see <linkHtml href="#ID_418ae3cd-c319-42ae-889f-6ae77ed072bb">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Refeeding syndrome <content styleCode="italics">[see <linkHtml href="#ID_93b1819b-88e2-4106-877e-70f0363e72bb">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hyperglycemia or hyperosmolar hyperglycemic state <content styleCode="italics">[see <linkHtml href="#ID_7cc66c01-4492-4e1a-b662-e01fad00175d">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Vein damage and thrombosis <content styleCode="italics">[see <linkHtml href="#ID_cdd06e8c-49b3-488c-9188-8c65bcb9c629">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hepatobiliary disorders <content styleCode="italics">[see <linkHtml href="#ID_3ee45b92-3db4-4fd4-b16b-a5bc63cee797">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Aluminum toxicity <content styleCode="italics">[see <linkHtml href="#ID_6ebe023c-1a4a-4275-a7f4-66ddf5f777b1">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Parenteral Nutrition Associated Liver Disease (PNALD) <content styleCode="italics">[see <linkHtml href="#ID_8a6fbf0c-fbaa-4b76-b8cd-7eb740171a7f">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Electrolyte imbalance and fluid overload <content styleCode="italics">[see <linkHtml href="#ID_5c8d643b-c601-4f26-9a48-01aec9bc8490">Warnings and Precautions (5.10)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20201007"/>
            </section>
         </component>
         <component>
            <section ID="ID_0548aaef-9ec3-4dd5-88b1-7ebf3bf79403">
               <id root="bf3c40bb-c313-4099-9122-e57767c88494"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare Corporation<br/>
                     </content>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>Baxter and Travasol are registered trademarks of Baxter International Inc.</paragraph>
               </text>
               <effectiveTime value="20201007"/>
            </section>
         </component>
         <component>
            <section ID="ID_6014E484-AC57-48EE-B2F5-29F037B43049">
               <id root="63d2a3d8-a4a4-49da-a3e8-247ab915f82a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <renderMultiMedia ID="id-1907289119" referencedObject="CE108B36-2A00-4773-A09B-C484F0D1B05C">
                     <caption>Container Label </caption>
                  </renderMultiMedia>
                  <paragraph>Container Label </paragraph>
                  <paragraph>
                     <content styleCode="bold">1B6624   1000 mL</content>
                     <br/>NDC 0338-0644-04</paragraph>
                  <paragraph>
                     <content styleCode="bold">10% TRAVASOL</content>
                     <br/>
                     <content styleCode="bold">10%</content>
                     <br/>
                     <content styleCode="bold">(Amino Acid)</content>
                     <br/>
                     <content styleCode="bold">Injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharmacy Bulk Package</content>
                     <br/>
                     <content styleCode="bold">Not For Direct Infusion</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>EACH 100mL CONTAINS <content styleCode="bold">ESSENTIAL AMINO ACIDS</content> LEUCINE 730 mg  <br/>ISOLEUCINE 600 mg  LYSINE(ADDED AS THE HYDROCHLORIDE SALT) 580 mg  VALINE 580 mg PHENYLALANINE 560 mg  HISTIDINE 480 mg  <br/>THREONINE 420 mg    METHIONINE 400 mg  TRYPTOPHAN 180 mg  <br/>
                     <content styleCode="bold">NONESSENTIALAMINO ACIDS</content>  ALANINE 2.07 g  ARGININE 1.15 g <br/>GLYCINE 1.03 g PROLINE 680 mg  SERINE 500 mg  TYROSINE 40 mg<br/>pH ADJUSTED WITH GLACIAL ACETIC ACID  pH 6.0 (5.0 TO 7.0) </paragraph>
                  <paragraph>mEq/L*  ACETATE - 88  CHLORIDE - 40<br/>*BALANCED BY IONS FROM AMINO ACIDS<br/>HYPERTONIC  OSMOLARITY 998 mOsmo/L (CALC)<br/>STERILE NONPYROGENIC</paragraph>
                  <paragraph>CONTAINS NO MORE THAN 25 µg/L OF ALUMINUM</paragraph>
                  <paragraph>ADDITIVES MAY BE INCOMPATIBLE WITH THE FLUID WITHDRAWN <br/>FROM THIS CONTAINER  CONSULT WITH PHARMACIST IF AVAILABLE  <br/>WHEN COMPOUNDING ADMIXTURES USE ASEPTIC TECHNIQUE  <br/>MIX THOROUGHLY  DO NOT STORE</paragraph>
                  <paragraph>DOSAGE ADMIX FOR INTRAVENOUS ADMINISTRATION AS DIRECTED <br/>BY A   PHYSICIAN  SEE ACCOMPANYING DIRECTIONS FOR USE </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE CONTAINER CLOSURE HAS BEEN PENETRATED </content>
                     <br/>
                     <content styleCode="bold">WITHDRAWAL OF CONTENTS SHOULDBE COMPLETED </content>
                     <br/>
                     <content styleCode="bold">WITHOUT DELAY</content>  AFFIX ACCOMPANYING LABEL FOR DATE<br/>AND TIME OF ENTRY  DISPENSE CONTENTS WITHIN 4 HOURS <br/>AFTER INITIAL ENTRY</paragraph>
                  <paragraph>CAUTION DO NOT USE UNLESS SOLUTION IS CLEAR AND <br/>SEAL IS INTACT</paragraph>
                  <paragraph>A SLIGHT YELLOW COLOR DOES NOT ALTER THE QUALITY AND <br/>EFFICACY OF THE PRODUCT</paragraph>
                  <paragraph>
                     <content styleCode="bold">VIAFLEX</content> CONTAINER</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">Baxter</content> Logo</content>
                     <br/>
                     <content styleCode="bold">BAXTER HEALTHCARE CORPORATION</content>
                     <br/>DEERFIELD IL 60015 USA  </paragraph>
                  <paragraph>MADE IN BELGIUM</paragraph>
                  <paragraph>PL 146 PLASTIC<br/>BAXTER TRAVASOL AND VIAFLEX <br/>ARE TRADEMARKS OF<br/>BAXTER INTERNATIONAL INC</paragraph>
                  <paragraph>EXP YYYY-MM</paragraph>
                  <paragraph>BE-35-04-035</paragraph>
                  <paragraph>1 2 3 4 5 6 7 8 9</paragraph>
                  <renderMultiMedia ID="id-37594933" referencedObject="F0A00673-5BE6-486A-A71F-219A87A16311">
                     <caption>Carton Label </caption>
                  </renderMultiMedia>
                  <paragraph>Carton Label </paragraph>
                  <paragraph>Lot: xx<br/>Qty: 24-500mL</paragraph>
                  <paragraph>Exp: x  x<br/>Code: 1B6623</paragraph>
                  <paragraph>NDC: 0338-0644-03</paragraph>
                  <paragraph>10% Travasol (Amino Acid) INJ Viaflex<br/>Container</paragraph>
                  <paragraph>(17) XX00 (10) xx</paragraph>
                  <paragraph>(01) 50303380644037</paragraph>
                  <paragraph>07/31/09  10:24:28</paragraph>
                  <paragraph>07-35-C</paragraph>
               </text>
               <effectiveTime value="20201007"/>
               <component>
                  <observationMedia ID="CE108B36-2A00-4773-A09B-C484F0D1B05C">
                     <text>Representative Container Label  0338-0644-04</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="F0A00673-5BE6-486A-A71F-219A87A16311">
                     <text>RepresentativeTravasol Carton Label   0338-0644-03</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>